NASDAQ:DERM Journey Medical Q3 2026 Earnings Date & Estimates $4.47 +0.17 (+3.95%) Closing price 11/6/2026 04:00 PM EasternExtended Trading$4.49 +0.02 (+0.45%) As of 11/6/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Journey Medical is estimated to report Q3 2026 earnings on Thursday, November 12, 2026, after market closes. The conference call is scheduled for 4:30 PM ET. Research:ProfileEarnings HistoryForecast Upcoming Earnings Announcement QuarterQ3 2026Announcement DateNovember 12, 2026TimeAfter Market ClosesConference Call4:30 PM ET Add to CalendarGoogle Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab) What Analysts Expect from Journey Medical in Q3 2026Journey Medical is expected to post earnings of -$0.03 per share on revenue of $20.32 million. In the same quarter a year earlier Journey Medical reported -$0.09 per share on revenue of $17.63 million. Journey Medical last reported on August 12, 2026, posting -$0.01 per share and beating the -$0.0225 consensus estimate. Journey Medical has beaten the consensus EPS estimate in 4 of its last 8 quarters.Consensus EstimatesConsensus EPS-$0.03Expected Revenue$20.32 millionPrior-Year EPS-$0.09Prior-Year Revenue$17.63 millionExpected Revenue Growth+15.3%Recent Track RecordLast ReportedQ2 2026Last Quarter EPS-$0.01 (Beat by +$0.0125)Last Quarter Revenue$18.51 millionEPS Beat Rate4 of last 8 quartersPrepare for the Q3 2026 CallEarnings HistoryCompany ProfileQ2 2026 Earnings ReportQ1 2026 Earnings ReportQ4 2025 Earnings Report Journey Medical Q3 2026 Earnings FAQ When does Journey Medical report Q3 2026 earnings? Journey Medical (NASDAQ:DERM) is estimated to report Q3 2026 earnings on Thursday, November 12, 2026, after market closes. This date is estimated from past reporting schedules and may change once the company confirms it. What time is Journey Medical's Q3 2026 earnings call? Journey Medical's Q3 2026 earnings conference call is scheduled for Thursday, November 12, 2026 at 4:30 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date. What is the consensus EPS estimate for Journey Medical? Analysts expect Journey Medical to post earnings of -$0.03 per share for Q3 2026. How much revenue is Journey Medical expected to report? The consensus revenue estimate for Journey Medical is $20.32 million for Q3 2026. Journey Medical Earnings HeadlinesJourney Medical Corporation to Announce Third Quarter 2026 Financial Results on November 12, 2026November 5 at 8:30 AM | globenewswire.comWill Journey Medical Corporation (DERM) report negative Q3 earnings? What you should knowNovember 4, 2026 | msn.comFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American financial crashes over his 55-year career leading Weiss Ratings, the only conflict-free rating agency in the US. Now he says a $3 trillion problem could trigger a chain reaction of crashes and failures, causing a global freeze in financial markets.November 8 at 1:00 AM | Weiss Ratings (Ad)HC Wainwright Reduces Earnings Estimates for Journey MedicalOctober 30, 2026 | americanbankingnews.comJourney Medical (NASDAQ:DERM) Earns "Buy" Rating from HC WainwrightOctober 28, 2026 | americanbankingnews.comAre options traders betting on a big move in Journey Medical stock?September 21, 2026 | msn.comSee More Journey Medical Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Journey Medical? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Journey Medical and other key companies, straight to your email. Email Address About Journey MedicalJourney Medical (NASDAQ:DERM) is a commercial-stage pharmaceutical company focused on developing and commercializing prescription products for medical dermatology. The company targets conditions that affect the skin, hair and nails, with an emphasis on products that address significant patient needs and can be marketed through its specialty sales organization. Its portfolio includes Qbrexza (glycopyrronium) cloth, a topical treatment for primary axillary hyperhidrosis, and Targadox (doxycycline hyclate) delayed-release capsules, which are used to treat moderate-to-severe inflammatory acne vulgaris. Journey Medical also markets dermatology products such as isotretinoin, a treatment for severe recalcitrant nodular acne, and Exelderm (sulconazole nitrate), an antifungal medication. Journey Medical was established in 2014 and is based in the United States. Its commercial activities primarily serve the U.S. dermatology market through relationships with dermatologists, other healthcare professionals and patients. Claude Maraoui is the company’s co-founder, president and chief executive officer.View Journey Medical ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 11/2 - 11/6IonQ's Record Revenue Includes a Big SkyWater Boost: Does That Change the Story?The Ugly Truth Behind SoundHound’s Q3 ResultsSandisk Shares Are Oversold: Bargain or Value Trap?Airbnb Defied a Brutal Tech Sell-Off, But Can Its Post-Earnings Rally Last?CVS Raised Its Outlook and Announced a Breakup—So Why Did the Stock Drop?Dutch Bros Gave Wall Street What It Wanted, So Why Did the Stock Crater? Upcoming Earnings Occidental Petroleum (11/9/2026)KKR & Co. Inc. (11/9/2026)Barrick Mining (11/9/2026)Constellation Energy (11/9/2026)Petroleo Brasileiro S.A.- Petrobras (11/10/2026)Transdigm Group (11/10/2026)Honda Motor (11/11/2026)Brookfield (11/12/2026)NU (11/12/2026)Applied Materials (11/12/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
